Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Sarepta Therapeutics Inc SRPT

Healthcare Biotechnology
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy... see more

Recent & Breaking News (NDAQ:SRPT)

SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Sarepta Therapeutics, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm

ACCESSWIRE IA January 15, 2021

IMPORTANT INVESTOR NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Sarepta Therapeutics, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm

ACCESSWIRE IA January 13, 2021

Sarepta Therapeutics and Genevant Sciences Announce Research Collaboration for Lipid Nanoparticle-Based Gene Editing Therapeutics

GlobeNewswire January 13, 2021

Sarepta Therapeutics, Inc. Investors: Company Investigated by the Portnoy Law Firm

GlobeNewswire January 12, 2021

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Sarepta Therapeutics, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm

Business Wire January 12, 2021

SHAREHOLDER ALERT: Barr Law Group Investigating the Officers and Directors of SRPT, PS, RP, and PGZ; Shareholders are Encouraged to Contact the Firm

GlobeNewswire January 12, 2021

SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Sarepta Therapeutics, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm

ACCESSWIRE IA January 11, 2021

SRPT Shareholder Alert - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Sarepta Therapeutics, Inc. Investigation

ACCESSWIRE IA January 11, 2021

SRPT Investor Alert - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Sarepta Therapeutics, Inc. Investigation

ACCESSWIRE IA January 10, 2021

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Sarepta Therapeutics, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm

ACCESSWIRE IA January 9, 2021

SRPT EQUITY ALERT: ROSEN, GLOBAL INVESTOR COUNSEL, Announces Investigation of Securities Claims Against Sarepta Therapeutics, Inc.; Encourages Investors with Losses Exceeding $1 Million to Contact Firm - SRPT

PR Newswire January 9, 2021

SRPT INVESTIGATION ALERT: Bernstein Liebhard is Investigating Sarepta Therapeutics, Inc. For Violations of the Securities Laws

PR Newswire January 8, 2021

SRPT EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Sarepta Therapeutics, Inc. - SRPT

Business Wire January 8, 2021

Sarepta Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 8, 2021

Sarepta Therapeutics Announces Top-line Results for Part 1 of Study 102 Evaluating SRP-9001, its Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy

GlobeNewswire January 7, 2021

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire December 31, 2020

Sarepta Therapeutics Announces Executive Management Changes

GlobeNewswire December 14, 2020

Sarepta Therapeutics Announces Positive Clinical Results from MOMENTUM, a Phase 2 Clinical Trial of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51

GlobeNewswire December 7, 2020

Sarepta Therapeutics to Share Clinical Update for SRP-5051, its Investigational PPMO for the Treatment of Duchenne Muscular Dystrophy

GlobeNewswire December 4, 2020

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire November 30, 2020